You can now review and comment on this draft guideline.
The consultation closes on 6 November 2017 at 5pm
How to comment
1. Register your organisation
Your organisation needs to be registered as a stakeholder before we can accept comments.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
2. Read the consultation documents
Documents to comment on:
- Short version of draft guideline – just the recommendations
- 1. Evidence review A - awareness of Lyme disease
- 2. Evidence review B - signs and symptoms
- 3. Evidence review C - diagnostic tests
- 4. Evidence review C - diagnostic tables
- 5. Evidence review D - management of erythema migrans
- 6. Evidence review E - management of non-specific symptoms
- 7. Evidence review F - management of neuroborreliosis
- 8. Evidence review G - management of Lyme arthritis
- 9. Evidence review H - management of acrodermatitis chronica atrophicans
- 10. Evidence review I - management of Lyme carditis
- 11. Evidence review J - management of lymphocytoma
- 12. Evidence review K - management of non-neurological ocular manifestations
- 13. Evidence review L - managmeent of persistent symptoms related to Lyme disease
- 14. Evidence review M - person to person transmission
- 15. Evidence review N - information needs
- Committee member list
- Economic model
If you want to review the economic model, please see 5. Economic models below and fill in the confidentiality form.
Other information about the consultation
3. Add your comments
- You must use this comments form.
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another organisation, send a joint response.
Make sure you consider:
- The areas that will have the biggest impact on practice and be challenging to implement
- How to help users overcome challenges
Developing NICE guidelines: how to get involved suggests some other areas to comment on.
4. Email the form to us
Deadline: 6 November 2017 at 5pm
5. Economic model
The Developer has produced an economic model to support the guideline on Lyme disease. To receive an executable version of this model, please submit a request to Lymedisease@nice.org.uk, with a signed copy of the confidentiality acknowledgement and undertaking form.
We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: 5pm on 6 November 2017.
- Economic models and their contents are confidential and are protected by intellectual property rights. They can only be used to inform your understanding of the guideline. They should not be used to inform the development of other economic models, and should not be re-run except to test reliability.
As set out on the confidentiality form:
- Models and their contents should only be shown to people in your organisation who need to see them to help you respond to the guideline consultation.
- You must ensure that anyone you show the files to understands that they are bound by the terms of the confidentiality acknowledgment and undertaking form.
- You must not copy the files, and must delete them from your records on publication of the guideline.
- You should not publish the model in whole or in part, or use them for any purpose other than participating in the consultation process.
Short version of draft guideline 574.35 KB
Committee member list 450.12 KB
Equality impact assessment 138.03 KB
Supporting documentation 282.82 KB
Supporting documentation Algorithm 79.59 KB
Evidence review A 703.26 KB
Evidence review B 1.12 MB
Evidence review C - TABLES 7.17 MB
Evidence review C 4.39 MB
Evidence review D 2.41 MB
Evidence review E 847.6 KB
Evidence review F 1.35 MB
Evidence review G 1.05 MB
Evidence review H 1.13 MB
Evidence review I 848.2 KB
Evidence review J 752.17 KB
Evidence review K 760.8 KB
Evidence review L 1.12 MB
Evidence review M 771.03 KB
Evidence review N 618.25 KB
Stakeholder list 37.72 KB
Confidentiality form 105.21 KB
Supporting documentation Methodology 707.64 KB
Comments form 61 KB
This page was last updated: 27 September 2017